1. Home
  2. LYEL vs ZVRA Comparison

LYEL vs ZVRA Comparison

Compare LYEL & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$23.86

Market Cap

490.1M

Sector

Health Care

ML Signal

HOLD

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$10.33

Market Cap

472.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LYEL
ZVRA
Founded
2018
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
490.1M
472.9M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
LYEL
ZVRA
Price
$23.86
$10.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$30.60
$23.00
AVG Volume (30 Days)
76.6K
694.8K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
159.21
EPS
N/A
1.35
Revenue
$36,000.00
$106,470,000.00
Revenue This Year
N/A
$37.27
Revenue Next Year
$16,285.34
$53.42
P/E Ratio
N/A
$7.26
Revenue Growth
N/A
350.91
52 Week Low
$0.39
$6.85
52 Week High
$45.00
$13.16

Technical Indicators

Market Signals
Indicator
LYEL
ZVRA
Relative Strength Index (RSI) 56.94 63.24
Support Level $21.27 $8.29
Resistance Level $27.30 $11.19
Average True Range (ATR) 1.70 0.40
MACD 0.50 0.06
Stochastic Oscillator 80.58 98.12

Price Performance

Historical Comparison
LYEL
ZVRA

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Share on Social Networks: